BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/26/2024 8:22:28 AM | Browse: 155 | Download: 730
 |
Received |
|
2024-08-03 19:55 |
|
Peer-Review Started |
|
2024-08-03 19:55 |
|
First Decision by Editorial Office Director |
|
2024-08-17 03:11 |
|
Return for Revision |
|
2024-08-17 03:11 |
|
Revised |
|
2024-08-29 02:50 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-09-10 02:47 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-09-10 06:19 |
|
Articles in Press |
|
2024-09-10 06:19 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-09-18 08:47 |
|
Publish the Manuscript Online |
|
2024-09-26 08:22 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yu-Qin Wang, Di Pan, Zhi-Yuan Yao, Yu-Qi Li, Peng-Fei Qu, Run-Bang Wang, Qing-Hao Gu, Jie Jiang, Zheng-Xiang Han and Hao-Nan Liu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hao-Nan Liu, Doctor, Doctor, Doctor, Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, No. 99 Huaihai West Road, Quanshan District, Xuzhou 221000, Jiangsu Province, China. why974300@163.com |
| Key Words |
Hepatocellular carcinoma; Camrelizumab; Lenvatinib; Efficacy; Safety |
| Core Tip |
Primary liver cancer is the sixth most common cancer and the third leading cause of cancer-related death worldwide, with hepatocellular carcinoma (HCC) being the most prevalent form. Numerous combination therapies involving programmed cell death protein 1/programmed cell death ligand 1 inhibitors and antiangiogenic targeted therapies have been investigated and approved as first-line systemic therapy for patients with advanced HCC. In the era of immune checkpoint inhibitors, nutritional assessment, including body mass index (BMI), can be considered a new prognostic predictor. However, the impact of BMI on the prognosis of patients with hepatitis B virus-related HCC remains controversial. We initiated a retrospective clinical study to explore the impact of BMI level on the prognosis of hepatitis B virus-related HCC patients treated with lenvatinib plus carelizumab. |
| Publish Date |
2024-09-26 08:22 |
| Citation |
Wang YQ, Pan D, Yao ZY, Li YQ, Qu PF, Wang RB, Gu QH, Jiang J, Han ZX, Liu HN. Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy. World J Gastroenterol 2024; 30(37): 4132-4148 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i37/4132.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i37.4132 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
